Dapagliflozin and Sitagliptin Combination Therapy: An Overview of Clinical Utility in Type 2 Diabetes Mellitus with Multiple Cardiovascular Risk Factors. Cardiology and Cardiovascular Medicine, v. 7, n. 2, p. 141–144, 24 Apr.2023.